Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Published Date: 13 Sep 2024

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

2.

For incarcerated people, study shows gaps exist in quality of cancer care

3.

Updates from the 2022 WHO classification of kidney epithelial tumors

4.

New research uncovers link between cancer pathway and blood-retina barrier function

5.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot